© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.
The Impact of Hurricane Maria on HIV
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.
The president tweeted a swift retort to the African-American head of Merck.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
